IGC Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IGC research report →
Price Chart
About the company
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage.
- CEO
- Ram Mukunda
- IPO
- 2006
- Employees
- 70
- HQ
- Potomac, MD, US
Get TickerSpark's AI analysis on IGC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.03M
- P/E
- -3.40
- PEG
- 0.35
- P/S
- 24.96
- P/B
- 4.58
- EV/EBITDA
- -3.87
- Div Yield
- 0.00%
- Gross Margin
- 21.91%
- Op Margin
- -986.82%
- Net Margin
- -702.14%
- ROE
- -113.58%
- ROIC
- -153.62%
Latest fiscal year · YoY change
- Revenue
- $1.19M-6.7%
- Gross Profit
- $352.00K-43.1%
- Op Income
- $-10,203,000
- Net Income
- $-6,548,000+8.0%
- EPS
- $-0.07+22.3%
- OCF Growth
- -23.9%
- FCF Growth
- -15.7%
- 52W High
- $0.45
- 52W Low
- $0.23
- 50D MA
- $0.28
- 200D MA
- $0.28
- Beta
- 0.48
- RSI (14)
- 50
- Avg Volume
- 710.49K
No earnings-call transcripts are available for IGC yet.
- Free Float
- 86.0%
- Shares Outstanding
- 100.09M
- Float Shares
- 86.08M
of shares held by institutions
35 13F filers
Buy/sell ratio 1.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.15M | 0 |
| Geode Capital Management, LLC | 879.39K | ▼ 163.99K |
| Vanguard Capital Management LLC | 814.91K | ▲ 96.48K |
| Blackrock, Inc. | 703.80K | 0 |
| Advisorshares Investments LLC | 678.48K | ▲ 678.48K |
| Citadel Advisors LLC | 437.32K | ▲ 437.32K |
| Vanguard Fiduciary Trust Co | 419.41K | ▲ 3.52K |
| Renaissance Technologies LLC | 286.61K | ▼ 197.37K |
| State Street Corp | 200.80K | 0 |
| Northern Trust Corp | 170.27K | ▲ 56.87K |
| Lawood & Co | 75.00K | 0 |
| Goldman Sachs Group Inc | 65.54K | 0 |
Held by 7 ETFs
Biggest fund positions in IGC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 26 | Mukunda Ram | other | 100,000 |
| Sep 25, 26 | Mukunda Ram | other | 100,000 |
| Sep 25, 26 | GRIMALDI CLAUDIA | other | 150,000 |
| Jun 30, 26 | Mukunda Ram | other | 2,226,475 |
| Jun 30, 26 | GRIMALDI CLAUDIA | other | 2,048,378 |
| Apr 1, 26 | PRINS RICHARD K | other | 70,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 100,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 70,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 100,000 |
| Apr 1, 26 | Mukunda Ram | other | 323,077 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IGC coverage
Recent articles, reports, and earnings notes.
No research on IGC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IGC report →IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%
defenseworld.net · Oct 3
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
accessnewswire.com · Sep 28
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
accessnewswire.com · Aug 17
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
accessnewswire.com · Aug 11
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
accessnewswire.com · Jul 29
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
accessnewswire.com · Jul 9
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
accessnewswire.com · Jul 7
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
accessnewswire.com · Jun 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.